An executive order
from President Donald Trump
calls for fast-tracking
research and access to
psychedelic medicines
for treatment of
mental health disorders.
What was your reaction
when you learned of
this executive order
that kind of
gives the FDA fast track?
So, the executive order
does several things
but the thing that I think
is going to have
the greatest impact on our work
and the psychedelic industry
as a whole
is that it is going to
accelerate the rate
at which the FDA
can evaluate drugs like this.
In particular
three companies got these
national program vouchers
that is going to accelerate
even more the speed at which
the FDA is reviewing
their applications for approval.
The concern that I have
quite honestly
is that the FDA
will approve this
sooner than we were expecting
and we don't really have
the capacity in terms of rooms
but especially the therapists
that are going to attend
to these individuals
to accommodate the demand
that's going to occur
when that happens.